Qureight Raises $20M Series B for AI Clinical Imaging

August 3, 2026

Fundraise Insider tracks newly funded startups each week and delivers verified B2B leads list of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Qureight, a Cambridge company building an AI imaging platform for clinical trials, has closed a $20 million Series B round led by Molten Ventures. The financing was announced on July 29, 2026.

Existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind and Ascension also took part. Qureight provides imaging and precision endpoints for trials, with a focus on lung and heart disease.

The company plans to expand its 3D deep learning imaging portfolio and grow commercially. Part of the money will go toward building an AI imaging laboratory to house its 3D chest imaging foundation model, which it says cuts both the data and the time needed to develop new disease models.

With the new capital, Qureight aims to bring products to market in areas including asthma, pulmonary hypertension, bronchiectasis and drug induced lung toxicity, adding to its existing work in lung fibrosis.

You may also like

35 Sales Email Tips to Crush Your Sales Game

In today’s digital age, email remains one of the most effective tools for reaching out to potential customers and driving sales. However, crafting a successful sales email can be tricky, as you need […]

Recently Funded Startups Are A Great Sales Target. Here’s Why.

The startup industry has been growing at an unprecedented rate in recent years, with billions of dollars being poured into the sector every year. This growth has created an opportunity for businesses to […]

How to Identify Your B2B Target Audience: A Comprehensive Guide

For any business to succeed, it is essential to target the right audience. In B2B marketing, identifying your target audience is even more important, as it helps you focus your efforts and resources […]